Key Developments: Skystar Bio-Pharmaceutical Co (SKBI.OQ)

SKBI.OQ on NASDAQ Stock Exchange Capital Market

4.25USD
12:34pm EST
Change (% chg)

$-0.08 (-1.85%)
Prev Close
$4.33
Open
$4.21
Day's High
$4.25
Day's Low
$4.21
Volume
7,750
Avg. Vol
6,310
52-wk High
$8.10
52-wk Low
$3.78

Search Stocks

Latest Key Developments (Source: Significant Developments)

Skystar Bio-Pharmaceutical Co reiterates FY 2014 revenue guidance
Friday, 14 Nov 2014 05:00pm EST 

Skystar Bio-Pharmaceutical Co:Reiterates FY 2014 guidance to be in range of $46 million to $50 million.  Full Article

Skystar Bio Pharmaceutical Co reaffirms FY 2014 revenue guidance
Thursday, 14 Aug 2014 06:59pm EDT 

Skystar Bio Pharmaceutical Co:Says that for FY 20104 it anticipates delivering an 8 pct. to 18 pct. year over year increase in top line revenue.Sees FY 2014 revenue range is $46 million to $50 million.  Full Article

Skystar Bio Pharmaceutical Co announces $5 mln registered direct offering
Wednesday, 16 Jul 2014 08:59am EDT 

Skystar Bio Pharmaceutical Co:Announces that it has entered into a definitive agreement with a dedicated healthcare institutional investor to purchase an aggregate of $5,000,000 of registered securities of the company in a registered direct offering.Pursuant to the terms of the agreement, the investor shall purchase from the company 790,514 shares of common stock and warrants to purchase up to 197,629 shares of common stock for an aggregate purchase price of $4,000,000.Says it shall use a portion of the proceeds of the offering for acquisitions, licenses of new vaccine and aquaculture products, research & development and other general corporate purposes.  Full Article

Skystar Bio Pharmaceutical Co reaffirms FY 2014 revenue guidance
Thursday, 15 May 2014 05:01pm EDT 

Skystar Bio Pharmaceutical Co:Maintains business outlook and anticipates delivering an 8pct to 18pct year over year increase in top line revenue for FY 2014 as compared to FY 2013.Expects revenue range of $46 million to $50 million for FY 2014.  Full Article

Skystar Bio Pharmaceutical Co gives FY 2014 revenue guidance
Monday, 31 Mar 2014 07:04pm EDT 

Skystar Bio Pharmaceutical Co:Sees 8 pct. to 18 pct. year over year increase in top line revenue for FY 2014 as compared to the prior year.Says the expected FY 2014 revenue range is $46 million to $50 million.  Full Article

Skystar Bio Pharmaceutical Co Reaffirms FY 2013 Revenue Guidance
Friday, 15 Nov 2013 05:00am EST 

Skystar Bio-Pharmaceutical Company reiterated fiscal 2013 revenue guidance to be in the range of $40 million to $45 million.  Full Article

Skystar Bio Pharmaceutical Co Reaffirms FY 2013 Revenue Guidance
Thursday, 16 May 2013 05:00am EDT 

Skystar Bio-Pharmaceutical Company reiterated fiscal 2013 revenue guidance to be in the range of $40 million to $45 million.  Full Article

Search Stocks